GlassScriptPhysician profile
Geza Remak
NPI 1588647150
$7,507.30
in general payments reported to CMS, 2019-2025
29 companies · $99.49 in 2025
The $99.49 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $241 · 2021: $531 · 2022: $2,641 · 2023: $2,379 · 2024: $111 · 2025: $99.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,858.20 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,386.83 | 2019-2023 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $357.18 | 2019-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $348.43 | 2019-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $284.96 | 2019-2023 | Entyvio |
| Nestle Healthcare Nutrition INC. | $231.52 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $231.13 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $229.11 | 2019-2023 | Stelara, Remicade, Simponi |
| Celgene Corporation | $221.28 | 2022-2023 | Zeposia |
| Pfizer INC. | $219.72 | 2019-2023 | |
| Qol Medical, LLC | $198.19 | 2021-2022 | |
| Gilead Sciences, INC. | $138.12 | 2019-2021 | |
| Ardelyx, INC. | $132.46 | 2023-2024 | Ibsrela |
| Redhill Biopharma INC. | $118.10 | 2021 | |
| Lilly USA, LLC | $99.49 | 2025 | Omvoh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $79.08 | 2023 | |
| Merck Sharp & Dohme LLC | $76.05 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $74.36 | 2019-2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $44.28 | 2021-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $28.40 | 2022 | |
| Evoke Pharma, INC. | $28.30 | 2023 | Gimoti |
| Ucb, INC. | $25.30 | 2019 | |
| Astellas Pharma US INC | $17.83 | 2023 | |
| Enterra Medical, INC. | $15.96 | 2023 | |
| Ambu INC. | $15.18 | 2022 | |
| Braintree Laboratories, INC. | $12.84 | 2019 | |
| Shire North American Group INC | $12.47 | 2019 | |
| Cook Medical LLC | $11.35 | 2020 | |
| Allergan, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geza Remak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.